On April 3, 2026, NeuroOne Medical Technologies Corporation announced the approval of an amendment to its 2025 Equity Incentive Plan during its Annual Meeting. The amendment allows for an increase in the aggregate number of shares of Common Stock that may be issued under the plan by 1,500,000 shares. Additionally, the plan will automatically increase the number of shares available for issuance by 5% of the Fully Diluted Shares at the end of each calendar year for five years, starting from January 1, 2027. This strategic move is expected to enhance the company's ability to attract and retain talent through equity compensation, which could positively impact its operational execution and strategy outlook. The amendment was approved by stockholders, reflecting their support for the company's growth initiatives. The meeting also saw the election of two Class III directors and the ratification of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending September 30, 2026. Furthermore, stockholders approved a reverse stock split of the company's outstanding common stock at a ratio to be determined by the Board of Directors, which may help improve the stock's market perception and liquidity. Overall, these developments indicate a proactive approach by NeuroOne to strengthen its governance and operational strategies, potentially leading to a positive effect on its stock price.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.